Login to Your Account



Lumena-sourced liver disease drug falls short in Shire's phase II trial

By Michael Fitzhugh
Staff Writer

Thursday, April 9, 2015

One of two major assets from Shire plc's multimillion-dollar Lumena Pharmaceuticals Inc. buy, SHP625 (LUM001), is shining a little less brightly after missing both primary and secondary endpoints in a small phase II study called IMAGO, which tested its ability to lower bile acid levels and minimize itching vs. placebo for children with Alagille syndrome (ALGS), a rare genetic disorder.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription